Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 48
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A Landscape of Pharmacogenomic Interactions in Cancer.

  • Iorio, Francesco Iorio
  • Tamborero Noguera, David
  • López Bigas, Núria
  • Esteller, Manel
  • Garnett, Mathew J.
Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature of cancer. Using this information to guide the development and application of therapies in the clinic is challenging. Here, we report how cancer-driven alterations identified in 11,289 tumors from 29 tissues (integrating somatic mutations, copy number alterations, DNA methylation, and gene expression) can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs. We find that cell lines faithfully recapitulate oncogenic alterations identified in tumors, find that many of these associate with drug sensitivity/resistance, and highlight the importance of tissue lineage in mediating drug response. Logic-based modeling uncovers combinations of alterations that sensitize to drugs, while machine learning demonstrates the relative importance of different data types in predicting drug response. Our analysis and datasets are rich resources to link genotypes with cellular phenotypes and to identify therapeutic options for selected cancer sub-populations., This work was funded by the Wellcome Trust (086375 and 102696). F.I. was supported by the European Bioinformatics Institute and Wellcome Trust Sanger Institute post-doctoral (ESPOD) program. T.A.K. was supported by the National Cancer Institute (U24CA143835) and the Netherlands Organization for Scientific Research. D.T. was supported by the People Programme (Marie Curie Actions) of the 7th Framework Programme of the European Union (FP7/2007-2013; 600388) and the Agency of Competitiveness for Companies of the Government of Catalonia (ACCIO´ ). N.L.-B. was supported by La Fundacio ´ la Marato´ de TV3. M.E. was funded by the European Research Council (268626), the Ministerio de Ciencia e Innovacion (SAF2011-22803), the Institute of Health Carlos III (ISCIII) under the Integrated Project of Excellence (PIE13/00022), the Spanish Cancer Research Network (RD12/0036/0039), the Health and Science Departments of the Catalan Government Generalitat de Catalunya 2014-SGR 633, and the Cellex Foundation. U.M. was supported by a Cancer Research UK Clinician Scientist Fellowship. We thank Aiqing He for expression data and Ilya Shmulevich for assistance with the LOBICO framework. We thank P. Campbell, M. Ranzani, J. Brammeld, M. Petljak, F. Behan, C. Alsinet Armengol, H. Francies, V. Grinkevich, and A. ‘‘Lilla’’ Mupo for useful comments. P.R.-M., H.C., and H.d.S. are employees and shareholders of Bristol-Myers Squibb. Research in the M.J.G. lab is supported in part with funding from AstraZeneca.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

DNA methylation contributes to natural human variation

  • Heyn, Holger
  • Moran, Sebastian
  • Hernando Herráez, Irene, 1985-
  • Sayols, Sergi
  • Gómez, Antonio
  • Sandoval, Juan
  • Monk, David
  • Hata, Kenichiro
  • Marquès i Bonet, Tomàs, 1975-
  • Wang, Liewei
  • Esteller, Manel
DNA methylation patterns are important for establishing cell, tissue, and organism phenotypes, but little is known about their contribution to natural human variation. To determine their contribution to variability, we have generated genome-scale DNA methylation profiles of three human populations (Caucasian-American, African-American, and Han Chinese-American) and examined the differentially methylated CpG sites. The distinctly methylated genes identified suggest an influence of DNA methylation on phenotype differences, such as susceptibility to certain diseases and pathogens, and response to drugs and environmental agents. DNA methylation differences can be partially traced back to genetic variation, suggesting that differentially methylated CpG sites serve as evolutionarily established mediators between the genetic code and phenotypic variability. Notably, one-third of the DNA methylation differences were not associated with any genetic variation, suggesting that variation in population-specific sites takes place at the genetic and epigenetic levels, highlighting the contribution of epigenetic modification to natural human variation, The research leading to these results received funding from the European Research Council (ERC) grant EPINORC under agreement number268626,ERC StartingGrant(260372),NIHgrantsCA138461 and GM61388 (Pharmacogenomics Research Network), the MICINN Projects SAF2011-22803 andBFU2011-28549,the CellexFoundation, the European Community’s Seventh Framework Programme (FP7/2007-2013) from grant HEALTH-F5-2011-282510 (BLUEPRINT), and the Health and Science Departments of the Generalitat de Catalunya. I.H.H. is a fellow of the Generalitat de Catalunya (FI 2011). T.M.B. and M.E. are ICREA Research Professors
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The interplay between DNA methylation and sequence divergence in recent human evolution

  • Hernando Herráez, Irene, 1985-
  • Heyn, Holger
  • Fernández Callejo, Marcos
  • Vidal, Enrique
  • Fernández Bellon, Hugo
  • Prado Martínez, Javier, 1987-
  • Sharp, Andrew J.
  • Esteller, Manel
  • Marquès i Bonet, Tomàs, 1975-
Despite the increasing knowledge about DNA methylation, the understanding of human epigenome evolution is in its infancy. Using whole genome bisulfite sequencing we identified hundreds of differentially methylated regions (DMRs) in humans compared to non-human primates and estimated that ∼25% of these regions were detectable throughout several human tissues. Human DMRs were enriched for specific histone modifications and the majority were located distal to transcription start sites, highlighting the importance of regions outside the direct regulatory context. We also found a significant excess of endogenous retrovirus elements in human-specific hypomethylated.We reported for the first time a close interplay between inter-species genetic and epigenetic variation in regions of incomplete lineage sorting, transcription factor binding sites and human differentially hypermethylated regions. Specifically, we observed an excess of human-specific substitutions in transcription factor binding sites located within human DMRs, suggesting that alteration of regulatory motifs underlies some human-specific methylation patterns. We also found that the acquisition of DNA hypermethylation in the human lineage is frequently coupled with a rapid evolution at nucleotide level in the neighborhood of these CpG sites. Taken together, our results reveal new insights into the mechanistic basis of human-specific DNA methylation patterns and the interpretation of inter-species non-coding variation., We acknowledge support from AGAUR (Generalitat de Catlunya, Spain) and the Barcelona Zoo (Ajuntament de Barcelona) for an award to I.H.H. H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII).T.M.B. and M.E. are ICREA Research Professors. Funding for open access charge: European Research Council (ERC), grant EPINORC, under agreement No. 268626; MICINN Projects—SAF2011-22803 and BFU2011-28549; Cellex Foundation; European Community's Seventh Framework Programme (FP7/2007-2013), grant HEALTH-F5-2011-282510—BLUEPRINT, and the Health and Science Departments of the Generalitat de Catalunya.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences

  • Moran, Sebastian
  • Arribas, Carles
  • Esteller, Manel, 1968-
DNA methylation is the best known epigenetic mark. Cancer and other pathologies show an altered DNA methylome. However, delivering complete DNA methylation maps is compromised by the price and labor-intensive interpretation of single nucleotide methods. MATERIAL & METHODS: Following the success of the HumanMethylation450 BeadChip (Infinium) methylation microarray (450K), we report the technical and biological validation of the newly developed MethylationEPIC BeadChip (Infinium) microarray that covers over 850,000 CpG methylation sites (850K). The 850K microarray contains >90% of the 450K sites, but adds 333,265 CpGs located in enhancer regions identified by the ENCODE and FANTOM5 projects. RESULTS & CONCLUSION: The 850K array demonstrates high reproducibility at the 450K CpG sites, is consistent among technical replicates, is reliable in the matched study of fresh frozen versus formalin-fixed paraffin-embeded samples and is also useful for 5-hydroxymethylcytosine. These results highlight the value of the MethylationEPIC BeadChip as a useful tool for the analysis of the DNA methylation profile of the human genome.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

A landscape of pharmacogenomic interactions in cancer

  • Iorio, Francesco
  • Knijnenburg, Theo A.
  • Vis, Daniel J.
  • Bignell, Graham
  • Menden, Michael P.
  • Schubert, Michael
  • Aben, Nanne
  • Gonçalves, Emanuel
  • Barthorpe, Syd
  • Lightfoot, Howard
  • Cokelae, Thomas
  • Greninger, Patricia
  • Dyk, Ewald van
  • Chang, Han
  • Silva, Heshani de
  • Heyn, Holger
  • Deng, Xianming
  • Egan, Regina K.
  • Liu, Qingsong
  • Mironenko, Tatiana
  • Mitropoulos, Xeni
  • Richardson, Laura
  • Wang, Jinhua
  • Zhang, Tinghu
  • Moran, Sebastian
  • Sayols, Sergi
  • Soleimani, Maryam
  • Tamborero Noguera, David
  • López Bigas, Núria
  • Ross-Macdonald, Petra
  • Esteller, Manel, 1968-
  • Gray, Nathanael S.
  • Haber, Daniel A.
  • Stratton, Michael R.
  • Benes, Cyril H.
  • Wessels, Lodewyk F. A.
  • Saez-Rodriguez, Julia
  • McDermott, Ultan
  • Garnett, Mathew J.
Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature of cancer. Using this information to guide the development and application of therapies in the clinic is challenging. Here, we report how cancer-driven alterations identified in 11,289 tumors from 29 tissues (integrating somatic mutations, copy number alterations, DNA methylation, and gene expression) can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs. We find that cell lines faithfully recapitulate oncogenic alterations identified in tumors, find that many of these associate with drug sensitivity/resistance, and highlight the importance of tissue lineage in mediating drug response. Logic-based modeling uncovers combinations of alterations that sensitize to drugs, while machine learning demonstrates the relative importance of different data types in predicting drug response. Our analysis and datasets are rich resources to link genotypes with cellular phenotypes and to identify therapeutic options for selected cancer sub-populations.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Epigenetic loss of RNA‑methyltransferase NSUN5 in glioma targets ribosomes to drive stress adaptive translational program

  • Janin, Maxime
  • Ortiz‑Barahona, Vanessa
  • Esteller, Manel, 1968-
  • Castro de Moura, Manuel
  • Carrato, Cristina
  • Martínez Cardús, Anna
  • Llinàs-Arias, Pere
  • Soler, Marta
  • Nachmani, Daphna
  • Pelletier, Joffrey
  • Schumann, Ulrike
  • Calleja Cervantes, Maria E.
  • Moran, Sebastian
  • Guil, Sonia
  • Bueno Costa, Alberto
  • Piñeyro, David
  • Pérez Salvia, Montserrat
  • Rosselló-Tortella, Margalida
  • Piqué, Laia
  • Bech-Serra, Joan J.
  • Torre Gómez, Carolina de la
  • Vidal-Bel, August
  • Martínez Iniesta, María
  • Martín-Tejera, Juan F.
  • Villanueva Garatachea, Alberto
  • Arias, Alexandra
  • Cuartas, Isabel
  • Aransay, Ana M.
  • Morales La Madrid, Andrés
  • Carcaboso, Ángel M.
  • Santa-Maria Lopez, Vicente
  • Mora Graupera, Jaume
  • Fernández, Agustín F.
  • Fraga, Mario F.
  • Aldecoa Ansórregui, Iban
  • Pedrosa, Leire
  • Graus Ribas, Francesc
  • Martínez Soler, Fina
  • Tortosa i Moreno, Avelina
Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

The interplay between DNA methylation and sequence divergence in recent human evolution

  • Hernando Herraez, Irene
  • Heyn, Holger
  • Fernandez Callejo, Marcos
  • Vidal, Enrique
  • Fernandez Bellon, Hugo
  • Prado Martinez, Javier
  • Sharp, Andrew J.
  • Esteller, Manel, 1968-
  • Marquès i Bonet, Tomàs, 1975-
Despite the increasing knowledge about DNA methylation, the understanding of human epigenome evolution is in its infancy. Using whole genome bisulfite sequencing we identified hundreds of differentially methylated regions (DMRs) in humans compared to non-human primates and estimated that similar to 25% of these regions were detectable throughout several human tissues. Human DMRs were enriched for specific histone modifications and the majority were located distal to transcription start sites, highlighting the importance of regions outside the direct regulatory context. We also found a significant excess of endogenous retrovirus elements in human-specific hypomethylated. We reported for the first time a close interplay between inter-species genetic and epigenetic variation in regions of incomplete lineage sorting, transcription factor binding sites and human differentially hypermethylated regions. Specifically, we observed an excess of human-specific substitutions in transcription factor binding sites located within human DMRs, suggesting that alteration of regulatory motifs underlies some human-specific methylation patterns. We also found that the acquisition of DNA hypermethylation in the human lineage is frequently coupled with a rapid evolution at nucleotide level in the neighborhood of these CpG sites. Taken together, our results reveal new insights into the mechanistic basis of human-specific DNA methylation patterns and the interpretation of inter-species non-coding variation.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia

  • Ferreira, Humberto J.
  • Heyn, Holger
  • Vizoso, Miguel
  • Moutinho, Cátia
  • Vidal, Enrique
  • Gomez, A
  • Martínez Cardús, Anna
  • Simó-Riudalbas, Laia
  • Moran, Sebastian
  • Jost, E
  • Esteller, Manel, 1968-
Close to half of de novo acute myeloid leukemia (AML) cases do not exhibit any cytogenetic aberrations. In this regard, distortion of the DNA methylation setting and the presence of mutations in epigenetic modifier genes can also be molecular drivers of the disease. In recent years, somatic missense mutations of the DNA methyltransferase 3A (DNMT3A) have been reported in ~20% of AML patients; however, no obvious critical downstream gene has been identified that could explain the role of DNMT3A in the natural history of AML. Herein, using whole-genome bisulfite sequencing and DNA methylation microarrays, we have identified a key gene undergoing promoter hypomethylation-associated transcriptional reactivation in DNMT3 mutant patients, the leukemogenic HOX cofactor MEIS1. Our results indicate that, in the absence of mixed lineage leukemia fusions, an alternative pathway for engaging an oncogenic MEIS1-dependent transcriptional program can be mediated by DNMT3A mutations.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Linkage of DNA methylation quantitative trait loci to human cancer risk

  • Heyn, Holger
  • Sayols, Sergi
  • Moutinho, Cátia
  • Vidal, Enrique
  • Sanchez-Mut, Jose Vicente
  • Stefansson, Olafur A.
  • Nadal, Ernest
  • Moran, Sebastian
  • Eyfjord, Jorunn E.
  • González Suárez, Eva
  • Pujana Genestar, M. Ángel
  • Esteller, Manel, 1968-
Epigenetic regulation and, in particular, DNA methyl- ation have been linked to the underlying genetic sequence. DNA methylation quantitative trait loci (meQTL) have been identified through significant associations between the genetic and epigenetic codes in physiological and pathological contexts. We propose that interrogating the interplay between polymorphic alleles and DNA methylation is a power- ful method for improving our interpretation of risk alleles identified in genome-wide association studies that otherwise lack mechanistic explanation. We integrated patient cancer risk genotype data and genome-scale DNA methylation profiles of 3,649 pri- mary human tumors, representing 13 solid cancer types. We provide a comprehensive meQTL catalog containing DNA methylation associations for 21% of interrogated cancer risk polymorphisms. Differen- tially methylated loci harbor previously reported and as-yet-unidentified cancer genes. We suggest that such regulation at the DNA level can provide a considerable amount of new information about the biology of cancer-risk alleles.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Epigenetic homogeneity within colorectal tumors predicts shorter relapse-free and overall survival times for patients with locoregional cancer

  • Martínez Cardús, Anna
  • Moran, Sebastian
  • Musulén, Eva
  • Moutinho, Cátia
  • Manzano, José Luis
  • Martínez Balibrea, Eva
  • Tierno, Montserrat
  • Élez, Elena
  • Landolfi, Stefania
  • Lorden, Patricia
  • Arribas, Carles
  • Müller, Fabian
  • Bock, Christoph
  • Esteller, Manel, 1968-
Background & aims: there are few validated biomarkers that can be used to predict outcomes for patients with colorectal cancer. Part of the challenge is the genetic and molecular heterogeneity of colorectal tumors not only among patients, but also within tumors. We have explored intratumor heterogeneity at the epigenetic level, due to its dynamic nature. We analyzed DNA methylation profiles of the digestive tract surface and the central bulk and invasive front regions of colorectal tumors. Methods: we determined the DNA methylation profiles of >450,000 CpG sites in 3 macrodissected regions of 79 colorectal tumors and 23 associated liver metastases, obtained from 2 hospitals in Spain. We also analyzed samples for KRAS and BRAF mutations, 499,170 single nucleotide polymorphisms, and performed immunohistochemical analyses. Results: we observed differences in DNA methylation among the 3 tumor sections; regions of tumor−host interface differed the most from the other tumor sections. Interestingly, tumor samples collected from areas closer to the gastrointestinal transit most frequently shared methylation events with metastases. When we calculated individual coefficients to quantify heterogeneity, we found that epigenetic homogeneity was significantly associated with short time of relapse-free survival (log-rank P = .037) and short time of overall survival (log-rank P = .026) in patients with locoregional colorectal cancer. Conclusions: in an analysis of 79 colorectal tumors, we found significant heterogeneity in patterns of DNA methylation within each tumor; the level of heterogeneity correlates with times of relapse-free and overall survival.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

MeCP2-E1 isoform is a dynamically expressed, weakly DNA-bound protein with different protein and DNA interactions compared to MeCP2-E2

  • Martínez de Paz, Alexia
  • Khajavi, Leila
  • Martin, Hélène
  • Clavería Gimeno, Rafael
  • Dieck, Susanne Tom
  • Cheema, Manjinder
  • Sanchez-Mut, Jose Vicente
  • Moksa, Malgorzata M.
  • Carles, Annaick
  • Brodie, Nick I.
  • Sheikh, Taimoor I.
  • Freeman, Melissa E.
  • Petrotchenko, Evgeniy V.
  • Borchers, Christoph H.
  • Schuman, Erin M.
  • Zytnicki, Matthias
  • Velazquez-Campoy, Adrian
  • Abian, Olga
  • Hirst, Martin
  • Esteller, Manel, 1968-
  • Vincent, John B.
  • Malnou, Cécile E.
  • Ausió, Juan
Background: MeCP2-a chromatin-binding protein associated with Rett syndrome-has two main isoforms, MeCP2-E1 and MeCP2-E2, differing in a few N-terminal amino acid residues. Previous studies have shown brain region-specific expression of these isoforms which, in addition to their different cellular localization and differential expression during brain development, suggest that they may also have non-overlapping molecular mechanisms. However, differential functions of MeCP2-E1 and E2 remain largely unexplored. Results: here, we show that the N-terminal domains (NTD) of MeCP2-E1 and E2 modulate the ability of the methyl-binding domain (MBD) to interact with DNA as well as influencing the turn-over rates, binding dynamics, response to neuronal depolarization, and circadian oscillations of the two isoforms. Our proteomics data indicate that both isoforms exhibit unique interacting protein partners. Moreover, genome-wide analysis using ChIP-seq provide evidence for a shared as well as a specific regulation of different sets of genes. Conclusions: our study supports the idea that Rett syndrome might arise from simultaneous impairment of cellular processes involving non-overlapping functions of MECP2 isoforms. For instance, MeCP2-E1 mutations might impact stimuli-dependent chromatin regulation, while MeCP2-E2 mutations could result in aberrant ribosomal expression. Overall, our findings provide insight into the functional complexity of MeCP2 by dissecting differential aspects of its two isoforms.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Mutations in JMJD1C are involved in Rett syndrome and intellectual disability

  • Sáez, Mauricio A.
  • Fernández Rodríguez, Juana
  • Moutinho, Cátia
  • Sanchez-Mut, Jose Vicente
  • Gómez, Antonio
  • Vidal, Enrique
  • Petazzi, Paolo
  • Szczesna, Karolina
  • López Serra, Paula
  • Lucariello, Mario
  • Lorden, Patricia
  • Delgado-Morales, Raul
  • Caridad, Olga J. de la
  • Huertas, Dori
  • Gelpí Buchaca, Josep Lluís
  • Orozco López, Modesto
  • López Dóriga Guerra, Adriana
  • Milà i Recasens, Montserrat
  • Pérez Jurado, Luis A.
  • Pineda, Mercedes
  • Armstrong i Morón, Judith
  • Lázaro García, Conxi
  • Esteller, Manel, 1968-
Purpose: autism spectrum disorders are associated with defects in social response and communication that often occur in the context of intellectual disability. Rett syndrome is one example in which epilepsy, motor impairment, and motor disturbance may co-occur. Mutations in histone demethylases are known to occur in several of these syndromes. Herein, we aimed to identify whether mutations in the candidate histone demethylase JMJD1C (jumonji domain containing 1C) are implicated in these disorders. Methods: we performed the mutational and functional analysis of JMJD1C in 215 cases of autism spectrum disorders, intellectual disability, and Rett syndrome without a known genetic defect. Results: we found seven JMJD1C variants that were not present in any control sample (~ 6,000) and caused an amino acid change involving a different functional group. From these, two de novo JMJD1C germline mutations were identified in a case of Rett syndrome and in a patient with intellectual disability. The functional study of the JMJD1C mutant Rett syndrome patient demonstrated that the altered protein had abnormal subcellular localization, diminished activity to demethylate the DNA damage-response protein MDC1, and reduced binding to MECP2. We confirmed that JMJD1C protein is widely expressed in brain regions and that its depletion compromises dendritic activity. Conclusions: our findings indicate that mutations in JMJD1C contribute to the development of Rett syndrome and intellectual disability.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer

  • Heyn, Holger
  • Vidal, Enrique
  • Ferreira, Humberto J.
  • Vizoso, Miguel
  • Sayols, Sergi
  • Gómez, Antonio
  • Moran, Sebastian
  • Boque-Sastre, Raquel
  • Guil, Sonia
  • Martínez Cardús, Anna
  • Lin, Charles Y.
  • Royo, Romina
  • Sanchez-Mut, Jose Vicente
  • Martínez, Ramón
  • Gut, Marta
  • Torrents Arenales, David
  • Orozco López, Modesto
  • Gut, Ivo G.
  • Young, Richard A.
  • Esteller, Manel, 1968-
Background: One of the hallmarks of cancer is the disruption of gene expression patterns. Many molecular lesions contribute to this phenotype, and the importance of aberrant DNA methylation profiles is increasingly recognized. Much of the research effort in this area has examined proximal promoter regions and epigenetic alterations at other loci are not well characterized. Results: Using whole genome bisulfite sequencing to examine uncharted regions of the epigenome, we identify a type of far-reaching DNA methylation alteration in cancer cells of the distal regulatory sequences described as super-enhancers. Human tumors undergo a shift in super-enhancer DNA methylation profiles that is associated with the transcriptional silencing or the overactivation of the corresponding target genes. Intriguingly, we observe locally active fractions of super-enhancers detectable through hypomethylated regions that suggest spatial variability within the large enhancer clusters. Functionally, the DNA methylomes obtained suggest that transcription factors contribute to this local activity of super-enhancers and that trans-acting factors modulate DNA methylation profiles with impact on transforming processes during carcinogenesis. Conclusions: We develop an extensive catalogue of human DNA methylomes at base resolution to better understand the regulatory functions of DNA methylation beyond those of proximal promoter gene regions. CpG methylation status in normal cells points to locally active regulatory sites at super-enhancers, which are targeted by specific aberrant DNA methylation events in cancer, with putative effects on the expression of downstream genes.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Epigenetic Disruption of the Piwi Pathway in Human Spermatogenic Disorders

  • Heyn, Holger
  • Ferreira, Humberto J.
  • Bassas, Lluís
  • Bonache, Sandra
  • Sayols, Sergi
  • Sandoval, Juan
  • Esteller, Manel, 1968-
  • Larriba, Sara
Epigenetic changes are involved in a wide range of common human diseases. Although DNA methylation defects are known to be associated with male infertility in mice, their impact on human deficiency of sperm production has yet to be determined. We have assessed the global genomic DNA methylation profiles in human infertile male patients with spermatogenic disorders by using the Infinium Human Methylation27 BeadChip. Three populations were studied: conserved spermatogenesis, spermatogenic failure due to germ cell maturation defects, and Sertoli cell-only syndrome samples. A disease-associated DNA methylation profile, characterized by targeting members of the PIWI-associated RNA (piRNA) processing machinery, was obtained. Bisulfite genomic sequencing and pyrosequencing in a large cohort (n = 46) of samples validated the altered DNA methylation patterns observed in piRNA-processing genes. In particular, male infertility was associated with the promoter hypermethylation-associated silencing of PIWIL2 and TDRD1. The downstream effects mediated by the epigenetic inactivation of the PIWI pathway genes were a defective production of piRNAs and a hypomethylation of the LINE-1 repetitive sequence in the affected patients. Overall, our data suggest that DNA methylation, at least that affecting PIWIL2/TDRD1, has a role in the control of gene expression in spermatogenesis and its imbalance contributes to an unsuccessful germ cell development that might explain a group of male infertility disorders.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA

  • Léveillé, Nicolas
  • Melo, Carlos A.
  • Rooijers, Koos
  • Diaz-Lagares, Angel
  • Melo, Sónia Rita Cardoso, 1978-
  • Korkmaz, Gozde
  • Lopes, Rui
  • Akbari Moqadam, Farhad
  • Maia, Ana R.
  • Wijchers, Patrick J.
  • Geeven, Geert
  • den Boer, Monique L.
  • Kalluri, Raghu
  • de Laat, Wouter
  • Esteller, Manel, 1968-
  • Agami, Reuven
p53 binds enhancers to regulate key target genes. Here, we globally mapped p53-regulated enhancers by looking at enhancer RNA (eRNA) production. Intriguingly, while many p53-induced enhancers contained p53-binding sites, most did not. As long non-coding RNAs(lncRNAs) are prominent regulators of chromatin dynamics, we hypothesized that p53-induced lncRNAs contribute to the activation of enhancers by p53. Among p53-induced lncRNAs, we identified LED and demonstrate that its suppression attenuates p53 function. Chromatin-binding and eRNA expression analyses show that LED associates with and activates strong enhancers. One prominent target of LED was located at an enhancer region within CDKN1A gene, a potent p53-responsive cell cycle inhibitor. LED knockdown reduces CDKN1A enhancer induction and activity, and cell cycle arrest following p53 activation. Finally, promoter-associated hypermethylation analysis shows silencing of LED in human tumours. Thus, our study identifies a new layer of complexity in the p53 pathway and suggests its dysregulation in cancer.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect

  • López Serra, Paula
  • Marcilla, Miguel
  • Villanueva Garatachea, Alberto
  • Ramos Fernandez, Antonio
  • Palau, Anna
  • Leal, Lucía
  • Wahi, Jessica E.
  • Setién, Fernando
  • Szczesna, Karolina
  • Moutinho, Cátia
  • Martínez Cardús, Anna
  • Heyn, Holger
  • Sandoval, Juan
  • Puertas, Sara
  • Vidal-Bel, August
  • Sanjuan, Xavier
  • Martínez Balibrea, Eva
  • Viñals Canals, Francesc
  • Perales Losa, Carlos
  • Bramsem, Jesper B.
  • Ørntoft, Torben F.
  • Andersen, Claus L.
  • Tabernero Caturla, Josep
  • McDermott, Ultan
  • Boxer, Matthew B.
  • Vander Heiden, Matthew G.
  • Albar, Juan Pablo
  • Esteller, Manel, 1968-
Cancer cells possess aberrant proteomes that can arise by the disruption of genes involved in physiological protein degradation. Here we demonstrate the presence of promoter CpG island hypermethylation-linked inactivation of DERL3 (Derlin-3), a key gene in the endoplasmic reticulum-associated protein degradation pathway, in human tumours. The restoration of in vitro and in vivo DERL3 activity highlights the tumour suppressor features of the gene. Using the stable isotopic labelling of amino acids in cell culture workflow for differential proteome analysis, we identify SLC2A1 (glucose transporter 1, GLUT1) as a downstream target of DERL3. Most importantly, SLC2A1 overexpression mediated by DERL3 epigenetic loss contributes to the Warburg effect in the studied cells and pinpoints a subset of human tumours with greater vulnerability to drugs targeting glycolysis.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Novel insights into DNA methylation features in spermatozoa: stability and peculiarities

  • Krausz, Csilla
  • Sandoval, Juan
  • Sayols, Sergi
  • Chianese, Chiara
  • Giachini, Claudia
  • Heyn, Holger
  • Esteller, Manel, 1968-
Data about the entire sperm DNA methylome are limited to two sperm donors whereas studies dealing with a greater number of subjects focused only on a few genes or were based on low resolution arrays. This implies that information about what we can consider as a normal sperm DNA methylome and whether it is stable among different normozoospermic individuals is still missing. The definition of the DNA methylation profile of normozoospermic men, the entity of inter-individual variability and the epigenetic characterization of quality-fractioned sperm subpopulations in the same subject (intra-individual variability) are relevant for a better understanding of pathological conditions. We addressed these questions by using the high resolution Infinium 450K methylation array and compared normal sperm DNA methylomes against somatic and cancer cells. Our study, based on the largest number of subjects (n = 8) ever considered for such a large number of CpGs (n = 487,517), provided clear evidence for i) a highly conserved DNA methylation profile among normozoospermic subjects; ii) a stable sperm DNA methylation pattern in different quality-fractioned sperm populations of the same individual. The latter finding is particularly relevant if we consider that different quality fractioned sperm subpopulations show differences in their structural features, metabolic and genomic profiles. We demonstrate, for the first time, that DNA methylation in normozoospermic men remains highly uniform regardless the quality of sperm subpopulations. In addition, our analysis provided both confirmatory and novel data concerning the sperm DNA methylome, including its peculiar features in respect to somatic and cancer cells. Our description about a highly polarized sperm DNA methylation profile, the clearly distinct genomic and functional organization of hypo- versus hypermethylated loci as well as the association of histone-enriched hypomethylated loci with embryonic development, which we now extended also to hypomethylated piRNAs-linked genes, provides solid basis for future basic and clinical research.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

DNA methylation contributes to natural human variation

  • Heyn, Holger
  • Moran, Sebastian
  • Hernando Herraez, Irene
  • Sayols, Sergi
  • Gomez, Antonio
  • Sandoval, Juan
  • Monk, Dave Nicholas
  • Hata, Kenichiro
  • Marques Bonet, Tomas
  • Wang, Liewei
  • Esteller, Manel, 1968-
DNA methylation patterns are important for establishing cell, tissue, and organism phenotypes, but little is known about their contribution to natural human variation. To determine their contribution to variability, we have generated genome-scale DNA methylation profiles of three human populations (Caucasian-American, African-American, and Han Chinese-American) and examined the differentially methylated CpG sites. The distinctly methylated genes identified suggest an influence of DNA methylation on phenotype differences, such as susceptibility to certain diseases and pathogens, and response to drugs and environmental agents. DNA methylation differences can be partially traced back to genetic variation, suggesting that differentially methylated CpG sites serve as evolutionarily established mediators between the genetic code and phenotypic variability. Notably, one-third of the DNA methylation differences were not associated with any genetic variation, suggesting that variation in population-specific sites takes place at the genetic and epigenetic levels, highlighting the contribution of epigenetic modification to natural human variation.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Circadian cycle-dependent MeCP2 and brain chromatin changes

  • Martínez de Paz, Alexia
  • Vicente Sanchez Mut, Jose
  • Samitier Martí, Mireia
  • Petazzi, Paolo
  • Sáez, Mauricio
  • Szczesna, Karolina
  • Huertas, Dori
  • Esteller, Manel, 1968-
  • Ausió, Juan
Abstract Methyl CpG binding protein 2 (MeCP2) is a chromosomal protein of the brain, very abundant especially in neurons, where it plays an important role in the regulation of gene expression. Hence it has the potential to be affected by the mammalian circadian cycle. We performed expression analyses of mice brain frontal cortices obtained at different time points and we found that the levels of MeCP2 are altered circadianly, affecting overall organization of brain chromatin and resulting in a circadian-dependent regulation of well-stablished MeCP2 target genes. Furthermore, this data suggests that alterations of MeCP2 can be responsible for the sleeping disorders arising from pathological stages, such as in autism and Rett syndrome.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

DNA methylation contributes to natural human variation

  • Heyn, Holger
  • Hernando-Herraez, Irene
  • Marqués-Bonet, Tomàs
  • Esteller, Manel
Heyn, Holger el al.-- This article, published in Genome Research, is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported)., DNA methylation patterns are important for establishing cell, tissue, and organism phenotypes, but little is known about their contribution to natural human variation. To determine their contribution to variability, we have generated genomescale DNA methylation profiles of three human populations (Caucasian-American, African-American, and Han Chinese-American) and examined the differentially methylated CpG sites. The distinctly methylated genes identified suggest an influence of DNA methylation on phenotype differences, such as susceptibility to certain diseases and pathogens, and response to drugs and environmental agents. DNA methylation differences can be partially traced back to genetic variation, suggesting that differentially methylated CpG sites serve as evolutionarily established mediators between the genetic code and phenotypic variability. Notably, one-third of the DNA methylation differences were not associated with any genetic variation, suggesting that variation in population-specific sites takes place at the genetic and epigenetic levels, highlighting the contribution of epigenetic modification to natural human variation. © 2013, Published by Cold Spring Harbor Laboratory Press., The research leading to these results received funding from the European Research Council (ERC) grant EPINORC under agreement number 268626, ERC Starting Grant (260372), NIH grants CA138461 and GM61388 (Pharmacogenomics Research Network), the MICINN Projects SAF2011-22803 and BFU2011-28549, the Cellex Foundation, the European Community's Seventh Framework Programme (FP7/2007-2013) from grant HEALTH-F5-2011-282510 (BLUEPRINT), and the Health and Science Departments of the Generalitat de Catalunya. I.H.H. is a fellow of the Generalitat de Catalunya (FI 2011)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The interplay between DNA methylation and sequence divergence in recent human evolution

  • Hernando-Herraez, Irene
  • Heyn, Holger
  • Fernández-Callejo, Marcos
  • Vidal, Enrique
  • Fernández-Bellón, Hugo
  • Prado-Martinez, Javier
  • Sharp, Andrew J.
  • Esteller, Manel
  • Marqués-Bonet, Tomàs
Despite the increasing knowledge about DNA methylation, the understanding of human epigenome evolution is in its infancy. Using whole genome bisulfite sequencing we identified hundreds of differentially methylated regions (DMRs) in humans compared to non-human primates and estimated that ∼25% of these regions were detectable throughout several human tissues. Human DMRs were enriched for specific histone modifications and the majority were located distal to transcription start sites, highlighting the importance of regions outside the direct regulatory context. We also found a significant excess of endogenous retrovirus elements in human-specific hypomethylated. We reported for the first time a close interplay between inter-species genetic and epigenetic variation in regions of incomplete lineage sorting, transcription factor binding sites and human differentially hypermethylated regions. Specifically, we observed an excess of human-specific substitutions in transcription factor binding sites located within human DMRs, suggesting that alteration of regulatory motifs underlies some human-specific methylation patterns. We also found that the acquisition of DNA hypermethylation in the human lineage is frequently coupled with a rapid evolution at nucleotide level in the neighborhood of these CpG sites. Taken together, our results reveal new insights into the mechanistic basis of human-specific DNA methylation patterns and the interpretation of inter-species non-coding variation., We acknowledge support from AGAUR (Generalitat de Catlunya, Spain) and the Barcelona Zoo (Ajuntament de Barcelona) for an award to I.H.H. H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII).T.M.B. and M.E. are ICREA Research Professors. Funding for open access charge: European Research Council (ERC), grant EPINORC, under agreement No. 268626; MICINN Projects—SAF2011-22803 and BFU2011-28549; Cellex Foundation; European Community's Seventh Framework Programme (FP7/2007-2013), grant HEALTH-F5-2011-282510—BLUEPRINT, and the Health and Science Departments of the Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis

  • Anadón, C.
  • Guil, S.
  • Simó-Riudalbas, L.
  • Moutinho, C.
  • Setien, F.
  • Martínez-Cardús, A.
  • Moran, S.
  • Villanueva, A.
  • Calaf, M.
  • Vidal, August
  • Lazo, Pedro A.
  • Zondervan, I.
  • Savola, S.
  • Kohno, T.
  • Yokota, J.
  • Pouplana, L. R. de
  • Esteller, M.
The introduction of new therapies against particular genetic mutations in non-small-cell lung cancer is a promising avenue for improving patient survival, but the target population is small. There is a need to discover new potential actionable genetic lesions, to which end, non-conventional cancer pathways, such as RNA editing, are worth exploring. Herein we show that the adenosine-toinosine editing enzyme ADAR1 undergoes gene amplification in non-small cancer cell lines and primary tumors in association with higher levels of the corresponding mRNA and protein. From a growth and invasion standpoint, the depletion of ADAR1 expression in amplified cells reduces their tumorigenic potential in cell culture and mouse models, whereas its overexpression has the opposite effects. From a functional perspective, ADAR1 overexpression enhances the editing frequencies of target transcripts such as NEIL1 and miR-381. In the clinical setting, patients with early-stage lung cancer, but harboring ADAR1 gene amplification, have poor outcomes. Overall, our results indicate a role for ADAR1 as a lung cancer oncogene undergoing gene amplification-associated activation that affects downstream RNA editing patterns and patient prognosis., This work was supported by the European Research Council under the European Community's Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no. 268626—EPINORC project, the Grant agreement number HEALTH-F2-2010-258677—CURELUNG project, the Spanish Ministry of Economy and Competitiveness (MINECO Projects no. SAF2011-22803, PI13-01339 and SAF2014-55000- R), the Institute of Health Carlos III (ISCIII)—PI10/02992, Ministerio de Educación, Ciencia e Innovación Grant SAF2010-14935, the Cellex Foundation, the National Cancer Center Research and Development Fund (NCC Biobank: 23 A-1) and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) AGAUR—project no. 2009SGR1315 and 2014SGR633., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MeCP2-E1 isoform is a dynamically expressed, weakly DNA-bound protein with diferent protein and DNA interactions compared to MeCP2-E2

  • Martínez de Paz, Alexia
  • Khajavi, Leila
  • Martin, Hélène
  • Claveria-Gimeno, Rafael
  • Dieck, S. T.
  • Cheema, Manjinder S.
  • Sánchez-Mut, José V.
  • Moksa, Malgorzata M.
  • Carles, Annaick
  • Brodie, Nick I.
  • Sheikh, Taimoor I.
  • Freenan, Melissa E.
  • Petrotchenko, Evgeniy V.
  • Borchers, Christoph H.
  • Schuman, Erin M.
  • Zytnicki, Matthias
  • Velázquez-Campoy, Adrián
  • Abian, Olga
  • Hirst, Martin
  • Estelller, Manel
  • Vincent, John B.
  • Malnou, Cécile E.
  • Ausió, Juan
16 pags., 5 figs.-- Open Access funded by Creative Commons Atribution Licence 4.0, BACKGROUND: MeCP2-a chromatin-binding protein associated with Rett syndrome-has two main isoforms, MeCP2-E1 and MeCP2-E2, differing in a few N-terminal amino acid residues. Previous studies have shown brain region-specific expression of these isoforms which, in addition to their different cellular localization and differential expression during brain development, suggest that they may also have non-overlapping molecular mechanisms. However, differential functions of MeCP2-E1 and E2 remain largely unexplored. RESULTS: Here, we show that the N-terminal domains (NTD) of MeCP2-E1 and E2 modulate the ability of the methyl-binding domain (MBD) to interact with DNA as well as influencing the turn-over rates, binding dynamics, response to neuronal depolarization, and circadian oscillations of the two isoforms. Our proteomics data indicate that both isoforms exhibit unique interacting protein partners. Moreover, genome-wide analysis using ChIP-seq provide evidence for a shared as well as a specific regulation of different sets of genes. CONCLUSIONS: Our study supports the idea that Rett syndrome might arise from simultaneous impairment of cellular processes involving non-overlapping functions of MECP2 isoforms. For instance, MeCP2-E1 mutations might impact stimuli-dependent chromatin regulation, while MeCP2-E2 mutations could result in aberrant ribosomal expression. Overall, our findings provide insight into the functional complexity of MeCP2 by dissecting differential aspects of its two isoforms., This work was supported by the Canadian Institutes of Health Research [MOP-130417 to JA and MOP-102758 to JBV]. Genome Canada and Genome British Columbia for fnancial support for the University of Victoria-Genome BC Proteomics Centre [204PRO and 214PRO], Leading Edge Endowment Fund (University of Victoria), the Segal McGill Chair in Molecular Oncology at McGill University, the Warren Y. Soper Charitable Trust and the Alvin Segal Family Foundation to the Jewish General Hospital to CHB. Max Planck Society and DFG CRC 1080; DFG CRC 902 to EMS. European Research Council under the European Union’s Horizon 2020 research and innovation program [743216 to EMS and 727264 (EPIPHARM) to ME]. Spanish Ministerio de Economia y Competitividad [BFU2013-47064-P and BFU2016-78232-P to AVC and SAF201455000-R to ME]. Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future”) [PI15/00663, and Miguel Servet contract CPII13/0017] to OA. Spanish Ministerio de Educacion Cultura y Deporte [FPU 13/3870] to RCG. Terry Fox Research Institute Program Project [TFRI #1039] and Canadian Cancer Society Research Institute [CCSRI #703489] to MH. European Community’s Seventh Framework Programme (FP7/2007–2013)/ERC [268626/ EPINORC project]; Integrated Project of Excellence [PIE13/00022] (ONCOPRO‑FILE); CIBER 2016 CB16/12/00312 (CIBERONC); the Spanish Cancer Research Network [RD12/0036/0039]; the Cellex Foundation; Obra Social “La Caixa”; and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) AGAUR [2014SGR633] to ME. ME is an ICREA Research Professor. French Association of Rett Syndrome funded research conducted by CEM, HM and LK, genotoul bioinformatics platform Toulouse Midi-Pyrenees (Bioinfo Genotoul) provided computing and storage resources., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

  • Janin, Maxime
  • Ortiz‑Barahona, Vanessa
  • Castro de Moura, Manuel
  • Martínez‑Cardús, Anna
  • Llinàs‑Arias, Pere
  • Soler, Marta
  • Nachmani, Daphna
  • Pelletier, Joffrey
  • Schumann, Ulrike
  • Calleja‑Cervantes, Maria E.
  • Morán, Sebastián
  • Guil, Sonia
  • Bueno-Costa, Alberto
  • Piñeyro, David
  • Perez‑Salvia, Montserrat
  • Rosselló‑Tortella, Margalida
  • Piqué, Laia
  • Bech‑Serra, Joan J.
  • Torre, Carolina de la
  • Vidal, August
  • Martínez‑Iniesta, María
  • Martín‑Tejera, Juan F.
  • Villanueva, Alberto
  • Arias, Alexandra
  • Cuartas, Isabel
  • Aransay, Ana M.
  • Morales La Madrid, Andres
  • Carcaboso, Ángel M.
  • Santa‑Maria, Vicente
  • Mora, Jaume
  • Fernández, Agustín F.
  • Fraga, Mario F.
  • Aldecoa, Iban
  • Pedrosa, Leire
  • Graus, Francesc
  • Vidal Sarró, Noemí
  • Martínez‑Soler, Fina
  • Tortosa, Avelina
  • Carrato, Cristina
  • Balañá, Carme
  • Boudreau, Matthew W.
  • Hergenrother, Paul J.
  • Kötter, Peter
  • Entian, Karl‑Dieter
  • Hench, Jürgen
  • Frank, Stephan
  • Mansouri, Sheila
  • Zadeh, Gelareh
  • Dans, Pablo D.
  • Orozco, Modesto
  • Thomas, George
  • Blanco, Sandra
  • Seoane, Joan
  • Preiss, Thomas
  • Pandolfi, Pier Paolo
  • Esteller, Manel
Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease., This work was supported by a European Research Council (ERC) Advanced Grant under the European Community’s Seventh Framework Program (FP7/2007-2013)/ERC Grant Agreement No. 268626—EPINORC project (to M. Esteller), the Ministerio de Economía y Competitividad (MINECO) under Grant No. SAF2014-55000-R (to M. Esteller) and the Instituto de Salud Carlos III (ISCIII), under the FIS PI16/01278 Project (to J. Seoane), the Integrated Project of Excellence no. PIE13/00022 (ONCOPROFILE) (to M. Esteller), CIBER 2016 CB16/12/00312 (CIBERONC) (to M. Esteller), co-financed by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF, the AGAUR—Catalan Government (Project No. 2009SGR1315 and 2014SGR633) (to M. Esteller), the Cellex Foundation (to M. Esteller), Obra Social “La Caixa” (to M. Esteller), the CERCA Program and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) (to M. Esteller) and a grant from the National Health and Medical Research Council of Australia (APP1061551, to TP). M.W. Boudreau is a member of the NIH Chemistry-Biology Interface Training Program (T32-GM070421).
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer

  • Heyn, Holger
  • Vidal, Enrique
  • Ferreira, Humberto J.
  • Vizoso, Miguel
  • Sayols, Sergi
  • Gomez, Antonio
  • Moran, Sebastian
  • Boque-Sastre, Raquel
  • Guil, Sonia
  • Martinez-Cardus, Anna
  • Lin, Charles Y.
  • Romina, Royo
  • Sanchez-Mut, Jose V.
  • Martinez, Ramon
  • Gut, Marta|||0000-0002-4063-7159
  • Torrents, David
  • Orozco, Modesto
  • Gut, Ivo
  • Young, Richard A.
  • Esteller, Manel
Background One of the hallmarks of cancer is the disruption of gene expression patterns. Many molecular lesions contribute to this phenotype, and the importance of aberrant DNA methylation profiles is increasingly recognized. Much of the research effort in this area has examined proximal promoter regions and epigenetic alterations at other loci are not well characterized. Results Using whole genome bisulfite sequencing to examine uncharted regions of the epigenome, we identify a type of far-reaching DNA methylation alteration in cancer cells of the distal regulatory sequences described as super-enhancers. Human tumors undergo a shift in super-enhancer DNA methylation profiles that is associated with the transcriptional silencing or the overactivation of the corresponding target genes. Intriguingly, we observe locally active fractions of super-enhancers detectable through hypomethylated regions that suggest spatial variability within the large enhancer clusters. Functionally, the DNA methylomes obtained suggest that transcription factors contribute to this local activity of super-enhancers and that trans-acting factors modulate DNA methylation profiles with impact on transforming processes during carcinogenesis. Conclusions We develop an extensive catalogue of human DNA methylomes at base resolution to better understand the regulatory functions of DNA methylation beyond those of proximal promoter gene regions. CpG methylation status in normal cells points to locally active regulatory sites at super-enhancers, which are targeted by specific aberrant DNA methylation events in cancer, with putative effects on the expression of downstream genes., The research leading to these results received funding from: the European Research Council (ERC), grant EPINORC, under agreement number 268626; MICINN Projects–SAF2011-22803 and BFU2011-28549; Ministerio de Economía y Competitividad (MINECO), co-financed by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF, under grant number SAF2014-55000-R; the Cellex Foundation; AGAUR Catalan Government Project #2009SGR1315; the Institute of Health Carlos III (ISCIII), under the Spanish Cancer Research Network (RTICC) number RD12/0036/0039, the Integrated Project of Excellence number PIE13/00022 (ONCOPROFILE) and the research grant PI11/00321; the Sandra Ibarra Foundation, under IV ghd Grants for breast cancer research; the Olga Torres Foundation; the European Community's Seventh Framework Programme (FP7/2007-2013), grant HEALTH-F5-2011-282510 – BLUEPRINT, and the Health and Science Departments of the Generalitat de Catalunya. H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII). D.T. and M.E. are ICREA Research Professors., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Epigenetic Disruption of the Piwi Pathway in Human Spermatogenic Disorders

  • Heyn, Holger
  • Ferreira, Humberto J.
  • Bassas, Lluís
  • Bonache, Sandra
  • Sayols, Sergi
  • Sandoval, Juan
  • Esteller, Manel
  • Larriba, Sara
Epigenetic changes are involved in a wide range of common human diseases. Although DNA methylation defects are known to be associated with male infertility in mice, their impact on human deficiency of sperm production has yet to be determined. We have assessed the global genomic DNA methylation profiles in human infertile male patients with spermatogenic disorders by using the Infinium Human Methylation27 BeadChip. Three populations were studied: conserved spermatogenesis, spermatogenic failure due to germ cell maturation defects, and Sertoli cell-only syndrome samples. A disease-associated DNA methylation profile, characterized by targeting members of the PIWI-associated RNA (piRNA) processing machinery, was obtained. Bisulfite genomic sequencing and pyrosequencing in a large cohort (n = 46) of samples validated the altered DNA methylation patterns observed in piRNA-processing genes. In particular, male infertility was associated with the promoter hypermethylation-associated silencing of PIWIL2 and TDRD1. The downstream effects mediated by the epigenetic inactivation of the PIWI pathway genes were a defective production of piRNAs and a hypomethylation of the LINE-1 repetitive sequence in the affected patients. Overall, our data suggest that DNA methylation, at least that affecting PIWIL2/TDRD1, has a role in the control of gene expression in spermatogenesis and its imbalance contributes to an unsuccessful germ cell development that might explain a group of male infertility disorders.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect

  • López Serra, Paula
  • Marcilla, Miguel
  • Villanueva Garatachea, Alberto
  • Ramos Fernandez, Antonio
  • Palau, Anna
  • Leal, Lucía
  • Wahi, Jessica E.
  • Setién, Fernando
  • Szczesna, Karolina
  • Moutinho, Cátia
  • Martínez Cardús, Anna
  • Heyn, Holger
  • Sandoval, Juan
  • Puertas, Sara
  • Vidal-Bel, August
  • Sanjuan, Xavier
  • Martínez Balibrea, Eva
  • Viñals Canals, Francesc
  • Perales Losa, Carlos
  • Bramsem, Jesper B.
  • Ørntoft, Torben F.
  • Andersen, Claus L.
  • Tabernero Caturla, Josep
  • McDermott, Ultan
  • Boxer, Matthew B.
  • Vander Heiden, Matthew G.
  • Albar, Juan Pablo
  • Esteller, Manel, 1968-
Cancer cells possess aberrant proteomes that can arise by the disruption of genes involved in physiological protein degradation. Here we demonstrate the presence of promoter CpG island hypermethylation-linked inactivation of DERL3 (Derlin-3), a key gene in the endoplasmic reticulum-associated protein degradation pathway, in human tumours. The restoration of in vitro and in vivo DERL3 activity highlights the tumour suppressor features of the gene. Using the stable isotopic labelling of amino acids in cell culture workflow for differential proteome analysis, we identify SLC2A1 (glucose transporter 1, GLUT1) as a downstream target of DERL3. Most importantly, SLC2A1 overexpression mediated by DERL3 epigenetic loss contributes to the Warburg effect in the studied cells and pinpoints a subset of human tumours with greater vulnerability to drugs targeting glycolysis.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Epigenetic homogeneity within colorectal tumors predicts shorter relapse-free and overall survival times for patients with locoregional cancer

  • Martínez Cardús, Anna
  • Moran, Sebastian
  • Musulén, Eva
  • Moutinho, Cátia
  • Manzano, José Luis
  • Martínez Balibrea, Eva
  • Tierno, Montserrat
  • Élez, Elena
  • Landolfi, Stefania
  • Lorden, Patricia
  • Arribas, Carles
  • Müller, Fabian
  • Bock, Christoph
  • Esteller, Manel
Background & aims: there are few validated biomarkers that can be used to predict outcomes for patients with colorectal cancer. Part of the challenge is the genetic and molecular heterogeneity of colorectal tumors not only among patients, but also within tumors. We have explored intratumor heterogeneity at the epigenetic level, due to its dynamic nature. We analyzed DNA methylation profiles of the digestive tract surface and the central bulk and invasive front regions of colorectal tumors. Methods: we determined the DNA methylation profiles of >450,000 CpG sites in 3 macrodissected regions of 79 colorectal tumors and 23 associated liver metastases, obtained from 2 hospitals in Spain. We also analyzed samples for KRAS and BRAF mutations, 499,170 single nucleotide polymorphisms, and performed immunohistochemical analyses. Results: we observed differences in DNA methylation among the 3 tumor sections; regions of tumor−host interface differed the most from the other tumor sections. Interestingly, tumor samples collected from areas closer to the gastrointestinal transit most frequently shared methylation events with metastases. When we calculated individual coefficients to quantify heterogeneity, we found that epigenetic homogeneity was significantly associated with short time of relapse-free survival (log-rank P = .037) and short time of overall survival (log-rank P = .026) in patients with locoregional colorectal cancer. Conclusions: in an analysis of 79 colorectal tumors, we found significant heterogeneity in patterns of DNA methylation within each tumor; the level of heterogeneity correlates with times of relapse-free and overall survival.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences

  • Moran, Sebastian
  • Arribas, Carles
  • Esteller, Manel
DNA methylation is the best known epigenetic mark. Cancer and other pathologies show an altered DNA methylome. However, delivering complete DNA methylation maps is compromised by the price and labor-intensive interpretation of single nucleotide methods. MATERIAL & METHODS: Following the success of the HumanMethylation450 BeadChip (Infinium) methylation microarray (450K), we report the technical and biological validation of the newly developed MethylationEPIC BeadChip (Infinium) microarray that covers over 850,000 CpG methylation sites (850K). The 850K microarray contains >90% of the 450K sites, but adds 333,265 CpGs located in enhancer regions identified by the ENCODE and FANTOM5 projects. RESULTS & CONCLUSION: The 850K array demonstrates high reproducibility at the 450K CpG sites, is consistent among technical replicates, is reliable in the matched study of fresh frozen versus formalin-fixed paraffin-embeded samples and is also useful for 5-hydroxymethylcytosine. These results highlight the value of the MethylationEPIC BeadChip as a useful tool for the analysis of the DNA methylation profile of the human genome.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer

  • Heyn, Holger
  • Vidal, Enrique
  • Ferreira, Humberto J.
  • Vizoso, Miguel
  • Sayols, Sergi
  • Gómez, Antonio
  • Moran, Sebastian
  • Boque-Sastre, Raquel
  • Guil, Sonia
  • Martínez Cardús, Anna
  • Lin, Charles Y.
  • Royo, Romina
  • Sanchez-Mut, Jose Vicente
  • Martínez, Ramón
  • Gut, Marta
  • Torrents Arenales, David
  • Orozco López, Modesto
  • Gut, Ivo G.
  • Young, Richard A.
  • Esteller, Manel
Background: One of the hallmarks of cancer is the disruption of gene expression patterns. Many molecular lesions contribute to this phenotype, and the importance of aberrant DNA methylation profiles is increasingly recognized. Much of the research effort in this area has examined proximal promoter regions and epigenetic alterations at other loci are not well characterized. Results: Using whole genome bisulfite sequencing to examine uncharted regions of the epigenome, we identify a type of far-reaching DNA methylation alteration in cancer cells of the distal regulatory sequences described as super-enhancers. Human tumors undergo a shift in super-enhancer DNA methylation profiles that is associated with the transcriptional silencing or the overactivation of the corresponding target genes. Intriguingly, we observe locally active fractions of super-enhancers detectable through hypomethylated regions that suggest spatial variability within the large enhancer clusters. Functionally, the DNA methylomes obtained suggest that transcription factors contribute to this local activity of super-enhancers and that trans-acting factors modulate DNA methylation profiles with impact on transforming processes during carcinogenesis. Conclusions: We develop an extensive catalogue of human DNA methylomes at base resolution to better understand the regulatory functions of DNA methylation beyond those of proximal promoter gene regions. CpG methylation status in normal cells points to locally active regulatory sites at super-enhancers, which are targeted by specific aberrant DNA methylation events in cancer, with putative effects on the expression of downstream genes.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A Landscape of Pharmacogenomic Interactions in Cancer.

  • Iorio, Francesco Iorio
  • Tamborero Noguera, David
  • López Bigas, Núria
  • Esteller, Manel
  • Garnett, Mathew J.
Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature of cancer. Using this information to guide the development and application of therapies in the clinic is challenging. Here, we report how cancer-driven alterations identified in 11,289 tumors from 29 tissues (integrating somatic mutations, copy number alterations, DNA methylation, and gene expression) can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs. We find that cell lines faithfully recapitulate oncogenic alterations identified in tumors, find that many of these associate with drug sensitivity/resistance, and highlight the importance of tissue lineage in mediating drug response. Logic-based modeling uncovers combinations of alterations that sensitize to drugs, while machine learning demonstrates the relative importance of different data types in predicting drug response. Our analysis and datasets are rich resources to link genotypes with cellular phenotypes and to identify therapeutic options for selected cancer sub-populations., This work was funded by the Wellcome Trust (086375 and 102696). F.I. was supported by the European Bioinformatics Institute and Wellcome Trust Sanger Institute post-doctoral (ESPOD) program. T.A.K. was supported by the National Cancer Institute (U24CA143835) and the Netherlands Organization for Scientific Research. D.T. was supported by the People Programme (Marie Curie Actions) of the 7th Framework Programme of the European Union (FP7/2007-2013; 600388) and the Agency of Competitiveness for Companies of the Government of Catalonia (ACCIO´ ). N.L.-B. was supported by La Fundacio ´ la Marato´ de TV3. M.E. was funded by the European Research Council (268626), the Ministerio de Ciencia e Innovacion (SAF2011-22803), the Institute of Health Carlos III (ISCIII) under the Integrated Project of Excellence (PIE13/00022), the Spanish Cancer Research Network (RD12/0036/0039), the Health and Science Departments of the Catalan Government Generalitat de Catalunya 2014-SGR 633, and the Cellex Foundation. U.M. was supported by a Cancer Research UK Clinician Scientist Fellowship. We thank Aiqing He for expression data and Ilya Shmulevich for assistance with the LOBICO framework. We thank P. Campbell, M. Ranzani, J. Brammeld, M. Petljak, F. Behan, C. Alsinet Armengol, H. Francies, V. Grinkevich, and A. ‘‘Lilla’’ Mupo for useful comments. P.R.-M., H.C., and H.d.S. are employees and shareholders of Bristol-Myers Squibb. Research in the M.J.G. lab is supported in part with funding from AstraZeneca.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Circadian cycle-dependent MeCP2 and brain chromatin changes

  • Martínez de Paz, Alexia
  • Vicente Sanchez Mut, Jose
  • Samitier Martí, Mireia
  • Petazzi, Paolo
  • Sáez, Mauricio
  • Szczesna, Karolina
  • Huertas, Dori
  • Esteller, Manel
  • Ausió, Juan
Abstract Methyl CpG binding protein 2 (MeCP2) is a chromosomal protein of the brain, very abundant especially in neurons, where it plays an important role in the regulation of gene expression. Hence it has the potential to be affected by the mammalian circadian cycle. We performed expression analyses of mice brain frontal cortices obtained at different time points and we found that the levels of MeCP2 are altered circadianly, affecting overall organization of brain chromatin and resulting in a circadian-dependent regulation of well-stablished MeCP2 target genes. Furthermore, this data suggests that alterations of MeCP2 can be responsible for the sleeping disorders arising from pathological stages, such as in autism and Rett syndrome.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer

  • Heyn, Holger
  • Vidal, Enrique
  • Ferreira, Humberto J.
  • Vizoso, Miguel
  • Sayols, Sergi
  • Gomez, Antonio
  • Moran, Sebastian
  • Boque-Sastre, Raquel
  • Guil, Sonia
  • Martinez-Cardus, Anna
  • Lin, Charles Y.
  • Romina, Royo
  • Sanchez-Mut, Jose V.
  • Martinez, Ramon
  • Gut, Marta
  • Torrents, David
  • Orozco, Modesto
  • Gut, Ivo
  • Young, Richard A.
  • Esteller, Manel
Background One of the hallmarks of cancer is the disruption of gene expression patterns. Many molecular lesions contribute to this phenotype, and the importance of aberrant DNA methylation profiles is increasingly recognized. Much of the research effort in this area has examined proximal promoter regions and epigenetic alterations at other loci are not well characterized. Results Using whole genome bisulfite sequencing to examine uncharted regions of the epigenome, we identify a type of far-reaching DNA methylation alteration in cancer cells of the distal regulatory sequences described as super-enhancers. Human tumors undergo a shift in super-enhancer DNA methylation profiles that is associated with the transcriptional silencing or the overactivation of the corresponding target genes. Intriguingly, we observe locally active fractions of super-enhancers detectable through hypomethylated regions that suggest spatial variability within the large enhancer clusters. Functionally, the DNA methylomes obtained suggest that transcription factors contribute to this local activity of super-enhancers and that trans-acting factors modulate DNA methylation profiles with impact on transforming processes during carcinogenesis. Conclusions We develop an extensive catalogue of human DNA methylomes at base resolution to better understand the regulatory functions of DNA methylation beyond those of proximal promoter gene regions. CpG methylation status in normal cells points to locally active regulatory sites at super-enhancers, which are targeted by specific aberrant DNA methylation events in cancer, with putative effects on the expression of downstream genes., The research leading to these results received funding from: the European Research Council (ERC), grant EPINORC, under agreement number 268626; MICINN Projects–SAF2011-22803 and BFU2011-28549; Ministerio de Economía y Competitividad (MINECO), co-financed by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF, under grant number SAF2014-55000-R; the Cellex Foundation; AGAUR Catalan Government Project #2009SGR1315; the Institute of Health Carlos III (ISCIII), under the Spanish Cancer Research Network (RTICC) number RD12/0036/0039, the Integrated Project of Excellence number PIE13/00022 (ONCOPROFILE) and the research grant PI11/00321; the Sandra Ibarra Foundation, under IV ghd Grants for breast cancer research; the Olga Torres Foundation; the European Community's Seventh Framework Programme (FP7/2007-2013), grant HEALTH-F5-2011-282510 – BLUEPRINT, and the Health and Science Departments of the Generalitat de Catalunya. H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII). D.T. and M.E. are ICREA Research Professors., Peer Reviewed, Postprint (author's final draft)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The interplay between DNA methylation and sequence divergence in recent human evolution

  • Hernando Herraez, Irene
  • Heyn, Holger
  • Fernandez Callejo, Marcos
  • Vidal, Enrique
  • Fernandez Bellon, Hugo
  • Prado Martinez, Javier
  • Sharp, Andrew J.
  • Esteller, Manel
  • Marquès i Bonet, Tomàs, 1975-
Despite the increasing knowledge about DNA methylation, the understanding of human epigenome evolution is in its infancy. Using whole genome bisulfite sequencing we identified hundreds of differentially methylated regions (DMRs) in humans compared to non-human primates and estimated that similar to 25% of these regions were detectable throughout several human tissues. Human DMRs were enriched for specific histone modifications and the majority were located distal to transcription start sites, highlighting the importance of regions outside the direct regulatory context. We also found a significant excess of endogenous retrovirus elements in human-specific hypomethylated. We reported for the first time a close interplay between inter-species genetic and epigenetic variation in regions of incomplete lineage sorting, transcription factor binding sites and human differentially hypermethylated regions. Specifically, we observed an excess of human-specific substitutions in transcription factor binding sites located within human DMRs, suggesting that alteration of regulatory motifs underlies some human-specific methylation patterns. We also found that the acquisition of DNA hypermethylation in the human lineage is frequently coupled with a rapid evolution at nucleotide level in the neighborhood of these CpG sites. Taken together, our results reveal new insights into the mechanistic basis of human-specific DNA methylation patterns and the interpretation of inter-species non-coding variation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The interplay between DNA methylation and sequence divergence in recent human evolution

  • Hernando Herráez, Irene, 1985-
  • Heyn, Holger
  • Fernández Callejo, Marcos
  • Vidal, Enrique
  • Fernández Bellon, Hugo
  • Prado Martínez, Javier, 1987-
  • Sharp, Andrew J.
  • Esteller, Manel
  • Marquès i Bonet, Tomàs, 1975-
Despite the increasing knowledge about DNA methylation, the understanding of human epigenome evolution is in its infancy. Using whole genome bisulfite sequencing we identified hundreds of differentially methylated regions (DMRs) in humans compared to non-human primates and estimated that ∼25% of these regions were detectable throughout several human tissues. Human DMRs were enriched for specific histone modifications and the majority were located distal to transcription start sites, highlighting the importance of regions outside the direct regulatory context. We also found a significant excess of endogenous retrovirus elements in human-specific hypomethylated.We reported for the first time a close interplay between inter-species genetic and epigenetic variation in regions of incomplete lineage sorting, transcription factor binding sites and human differentially hypermethylated regions. Specifically, we observed an excess of human-specific substitutions in transcription factor binding sites located within human DMRs, suggesting that alteration of regulatory motifs underlies some human-specific methylation patterns. We also found that the acquisition of DNA hypermethylation in the human lineage is frequently coupled with a rapid evolution at nucleotide level in the neighborhood of these CpG sites. Taken together, our results reveal new insights into the mechanistic basis of human-specific DNA methylation patterns and the interpretation of inter-species non-coding variation., We acknowledge support from AGAUR (Generalitat de Catlunya, Spain) and the Barcelona Zoo (Ajuntament de Barcelona) for an award to I.H.H. H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII).T.M.B. and M.E. are ICREA Research Professors. Funding for open access charge: European Research Council (ERC), grant EPINORC, under agreement No. 268626; MICINN Projects—SAF2011-22803 and BFU2011-28549; Cellex Foundation; European Community's Seventh Framework Programme (FP7/2007-2013), grant HEALTH-F5-2011-282510—BLUEPRINT, and the Health and Science Departments of the Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

MeCP2-E1 isoform is a dynamically expressed, weakly DNA-bound protein with different protein and DNA interactions compared to MeCP2-E2

  • Martínez de Paz, Alexia
  • Khajavi, Leila
  • Martin, Hélène
  • Clavería Gimeno, Rafael
  • Dieck, Susanne Tom
  • Cheema, Manjinder
  • Sanchez-Mut, Jose Vicente
  • Moksa, Malgorzata M.
  • Carles, Annaick
  • Brodie, Nick I.
  • Sheikh, Taimoor I.
  • Freeman, Melissa E.
  • Petrotchenko, Evgeniy V.
  • Borchers, Christoph H.
  • Schuman, Erin M.
  • Zytnicki, Matthias
  • Velazquez-Campoy, Adrian
  • Abian, Olga
  • Hirst, Martin
  • Esteller, Manel
  • Vincent, John B.
  • Malnou, Cécile E.
  • Ausió, Juan
Background: MeCP2-a chromatin-binding protein associated with Rett syndrome-has two main isoforms, MeCP2-E1 and MeCP2-E2, differing in a few N-terminal amino acid residues. Previous studies have shown brain region-specific expression of these isoforms which, in addition to their different cellular localization and differential expression during brain development, suggest that they may also have non-overlapping molecular mechanisms. However, differential functions of MeCP2-E1 and E2 remain largely unexplored. Results: here, we show that the N-terminal domains (NTD) of MeCP2-E1 and E2 modulate the ability of the methyl-binding domain (MBD) to interact with DNA as well as influencing the turn-over rates, binding dynamics, response to neuronal depolarization, and circadian oscillations of the two isoforms. Our proteomics data indicate that both isoforms exhibit unique interacting protein partners. Moreover, genome-wide analysis using ChIP-seq provide evidence for a shared as well as a specific regulation of different sets of genes. Conclusions: our study supports the idea that Rett syndrome might arise from simultaneous impairment of cellular processes involving non-overlapping functions of MECP2 isoforms. For instance, MeCP2-E1 mutations might impact stimuli-dependent chromatin regulation, while MeCP2-E2 mutations could result in aberrant ribosomal expression. Overall, our findings provide insight into the functional complexity of MeCP2 by dissecting differential aspects of its two isoforms.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

DNA methylation contributes to natural human variation

  • Heyn, Holger
  • Moran, Sebastian
  • Hernando Herráez, Irene, 1985-
  • Sayols, Sergi
  • Gómez, Antonio
  • Sandoval, Juan
  • Monk, David
  • Hata, Kenichiro
  • Marquès i Bonet, Tomàs, 1975-
  • Wang, Liewei
  • Esteller, Manel
DNA methylation patterns are important for establishing cell, tissue, and organism phenotypes, but little is known about their contribution to natural human variation. To determine their contribution to variability, we have generated genome-scale DNA methylation profiles of three human populations (Caucasian-American, African-American, and Han Chinese-American) and examined the differentially methylated CpG sites. The distinctly methylated genes identified suggest an influence of DNA methylation on phenotype differences, such as susceptibility to certain diseases and pathogens, and response to drugs and environmental agents. DNA methylation differences can be partially traced back to genetic variation, suggesting that differentially methylated CpG sites serve as evolutionarily established mediators between the genetic code and phenotypic variability. Notably, one-third of the DNA methylation differences were not associated with any genetic variation, suggesting that variation in population-specific sites takes place at the genetic and epigenetic levels, highlighting the contribution of epigenetic modification to natural human variation, The research leading to these results received funding from the European Research Council (ERC) grant EPINORC under agreement number268626,ERC StartingGrant(260372),NIHgrantsCA138461 and GM61388 (Pharmacogenomics Research Network), the MICINN Projects SAF2011-22803 andBFU2011-28549,the CellexFoundation, the European Community’s Seventh Framework Programme (FP7/2007-2013) from grant HEALTH-F5-2011-282510 (BLUEPRINT), and the Health and Science Departments of the Generalitat de Catalunya. I.H.H. is a fellow of the Generalitat de Catalunya (FI 2011). T.M.B. and M.E. are ICREA Research Professors
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Linkage of DNA methylation quantitative trait loci to human cancer risk

  • Heyn, Holger
  • Sayols, Sergi
  • Moutinho, Cátia
  • Vidal, Enrique
  • Sanchez-Mut, Jose Vicente
  • Stefansson, Olafur A.
  • Nadal, Ernest
  • Moran, Sebastian
  • Eyfjord, Jorunn E.
  • González Suárez, Eva
  • Pujana Genestar, M. Ángel
  • Esteller, Manel
Epigenetic regulation and, in particular, DNA methyl- ation have been linked to the underlying genetic sequence. DNA methylation quantitative trait loci (meQTL) have been identified through significant associations between the genetic and epigenetic codes in physiological and pathological contexts. We propose that interrogating the interplay between polymorphic alleles and DNA methylation is a power- ful method for improving our interpretation of risk alleles identified in genome-wide association studies that otherwise lack mechanistic explanation. We integrated patient cancer risk genotype data and genome-scale DNA methylation profiles of 3,649 pri- mary human tumors, representing 13 solid cancer types. We provide a comprehensive meQTL catalog containing DNA methylation associations for 21% of interrogated cancer risk polymorphisms. Differen- tially methylated loci harbor previously reported and as-yet-unidentified cancer genes. We suggest that such regulation at the DNA level can provide a considerable amount of new information about the biology of cancer-risk alleles.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA

  • Léveillé, Nicolas
  • Melo, Carlos A.
  • Rooijers, Koos
  • Diaz-Lagares, Angel
  • Melo, Sónia Rita Cardoso, 1978-
  • Korkmaz, Gozde
  • Lopes, Rui
  • Akbari Moqadam, Farhad
  • Maia, Ana R.
  • Wijchers, Patrick J.
  • Geeven, Geert
  • den Boer, Monique L.
  • Kalluri, Raghu
  • de Laat, Wouter
  • Esteller, Manel
  • Agami, Reuven
p53 binds enhancers to regulate key target genes. Here, we globally mapped p53-regulated enhancers by looking at enhancer RNA (eRNA) production. Intriguingly, while many p53-induced enhancers contained p53-binding sites, most did not. As long non-coding RNAs(lncRNAs) are prominent regulators of chromatin dynamics, we hypothesized that p53-induced lncRNAs contribute to the activation of enhancers by p53. Among p53-induced lncRNAs, we identified LED and demonstrate that its suppression attenuates p53 function. Chromatin-binding and eRNA expression analyses show that LED associates with and activates strong enhancers. One prominent target of LED was located at an enhancer region within CDKN1A gene, a potent p53-responsive cell cycle inhibitor. LED knockdown reduces CDKN1A enhancer induction and activity, and cell cycle arrest following p53 activation. Finally, promoter-associated hypermethylation analysis shows silencing of LED in human tumours. Thus, our study identifies a new layer of complexity in the p53 pathway and suggests its dysregulation in cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

DNA methylation contributes to natural human variation

  • Heyn, Holger
  • Moran, Sebastian
  • Hernando Herraez, Irene
  • Sayols, Sergi
  • Gomez, Antonio
  • Sandoval, Juan
  • Monk, Dave Nicholas
  • Hata, Kenichiro
  • Marques Bonet, Tomas
  • Wang, Liewei
  • Esteller, Manel
DNA methylation patterns are important for establishing cell, tissue, and organism phenotypes, but little is known about their contribution to natural human variation. To determine their contribution to variability, we have generated genome-scale DNA methylation profiles of three human populations (Caucasian-American, African-American, and Han Chinese-American) and examined the differentially methylated CpG sites. The distinctly methylated genes identified suggest an influence of DNA methylation on phenotype differences, such as susceptibility to certain diseases and pathogens, and response to drugs and environmental agents. DNA methylation differences can be partially traced back to genetic variation, suggesting that differentially methylated CpG sites serve as evolutionarily established mediators between the genetic code and phenotypic variability. Notably, one-third of the DNA methylation differences were not associated with any genetic variation, suggesting that variation in population-specific sites takes place at the genetic and epigenetic levels, highlighting the contribution of epigenetic modification to natural human variation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A landscape of pharmacogenomic interactions in cancer

  • Iorio, Francesco
  • Knijnenburg, Theo A.
  • Vis, Daniel J.
  • Bignell, Graham
  • Menden, Michael P.
  • Schubert, Michael
  • Aben, Nanne
  • Gonçalves, Emanuel
  • Barthorpe, Syd
  • Lightfoot, Howard
  • Cokelae, Thomas
  • Greninger, Patricia
  • Dyk, Ewald van
  • Chang, Han
  • Silva, Heshani de
  • Heyn, Holger
  • Deng, Xianming
  • Egan, Regina K.
  • Liu, Qingsong
  • Mironenko, Tatiana
  • Mitropoulos, Xeni
  • Richardson, Laura
  • Wang, Jinhua
  • Zhang, Tinghu
  • Moran, Sebastian
  • Sayols, Sergi
  • Soleimani, Maryam
  • Tamborero Noguera, David
  • López Bigas, Núria
  • Ross-Macdonald, Petra
  • Esteller, Manel
  • Gray, Nathanael S.
  • Haber, Daniel A.
  • Stratton, Michael R.
  • Benes, Cyril H.
  • Wessels, Lodewyk F. A.
  • Saez-Rodriguez, Julia
  • McDermott, Ultan
  • Garnett, Mathew J.
Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature of cancer. Using this information to guide the development and application of therapies in the clinic is challenging. Here, we report how cancer-driven alterations identified in 11,289 tumors from 29 tissues (integrating somatic mutations, copy number alterations, DNA methylation, and gene expression) can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs. We find that cell lines faithfully recapitulate oncogenic alterations identified in tumors, find that many of these associate with drug sensitivity/resistance, and highlight the importance of tissue lineage in mediating drug response. Logic-based modeling uncovers combinations of alterations that sensitize to drugs, while machine learning demonstrates the relative importance of different data types in predicting drug response. Our analysis and datasets are rich resources to link genotypes with cellular phenotypes and to identify therapeutic options for selected cancer sub-populations.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Epigenetic loss of RNA‑methyltransferase NSUN5 in glioma targets ribosomes to drive stress adaptive translational program

  • Janin, Maxime
  • Ortiz‑Barahona, Vanessa
  • Esteller, Manel
  • Castro de Moura, Manuel
  • Carrato, Cristina
  • Martínez Cardús, Anna
  • Llinàs-Arias, Pere
  • Soler, Marta
  • Nachmani, Daphna
  • Pelletier, Joffrey
  • Schumann, Ulrike
  • Calleja Cervantes, Maria E.
  • Moran, Sebastian
  • Guil, Sonia
  • Bueno Costa, Alberto
  • Piñeyro, David
  • Pérez Salvia, Montserrat
  • Rosselló-Tortella, Margalida
  • Piqué, Laia
  • Bech-Serra, Joan J.
  • Torre Gómez, Carolina de la
  • Vidal-Bel, August
  • Martínez Iniesta, María
  • Martín-Tejera, Juan F.
  • Villanueva Garatachea, Alberto
  • Arias, Alexandra
  • Cuartas, Isabel
  • Aransay, Ana M.
  • Morales La Madrid, Andrés
  • Carcaboso, Ángel M.
  • Santa-Maria Lopez, Vicente
  • Mora Graupera, Jaume
  • Fernández, Agustín F.
  • Fraga, Mario F.
  • Aldecoa Ansórregui, Iban
  • Pedrosa, Leire
  • Graus Ribas, Francesc
  • Martínez Soler, Fina
  • Tortosa i Moreno, Avelina
Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Novel insights into DNA methylation features in spermatozoa: stability and peculiarities

  • Krausz, Csilla
  • Sandoval, Juan
  • Sayols, Sergi
  • Chianese, Chiara
  • Giachini, Claudia
  • Heyn, Holger
  • Esteller, Manel
Data about the entire sperm DNA methylome are limited to two sperm donors whereas studies dealing with a greater number of subjects focused only on a few genes or were based on low resolution arrays. This implies that information about what we can consider as a normal sperm DNA methylome and whether it is stable among different normozoospermic individuals is still missing. The definition of the DNA methylation profile of normozoospermic men, the entity of inter-individual variability and the epigenetic characterization of quality-fractioned sperm subpopulations in the same subject (intra-individual variability) are relevant for a better understanding of pathological conditions. We addressed these questions by using the high resolution Infinium 450K methylation array and compared normal sperm DNA methylomes against somatic and cancer cells. Our study, based on the largest number of subjects (n = 8) ever considered for such a large number of CpGs (n = 487,517), provided clear evidence for i) a highly conserved DNA methylation profile among normozoospermic subjects; ii) a stable sperm DNA methylation pattern in different quality-fractioned sperm populations of the same individual. The latter finding is particularly relevant if we consider that different quality fractioned sperm subpopulations show differences in their structural features, metabolic and genomic profiles. We demonstrate, for the first time, that DNA methylation in normozoospermic men remains highly uniform regardless the quality of sperm subpopulations. In addition, our analysis provided both confirmatory and novel data concerning the sperm DNA methylome, including its peculiar features in respect to somatic and cancer cells. Our description about a highly polarized sperm DNA methylation profile, the clearly distinct genomic and functional organization of hypo- versus hypermethylated loci as well as the association of histone-enriched hypomethylated loci with embryonic development, which we now extended also to hypomethylated piRNAs-linked genes, provides solid basis for future basic and clinical research.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mutations in JMJD1C are involved in Rett syndrome and intellectual disability

  • Sáez, Mauricio A.
  • Fernández Rodríguez, Juana
  • Moutinho, Cátia
  • Sanchez-Mut, Jose Vicente
  • Gómez, Antonio
  • Vidal, Enrique
  • Petazzi, Paolo
  • Szczesna, Karolina
  • López Serra, Paula
  • Lucariello, Mario
  • Lorden, Patricia
  • Delgado-Morales, Raul
  • Caridad, Olga J. de la
  • Huertas, Dori
  • Gelpí Buchaca, Josep Lluís
  • Orozco López, Modesto
  • López Dóriga Guerra, Adriana
  • Milà i Recasens, Montserrat
  • Pérez Jurado, Luis A.
  • Pineda, Mercedes
  • Armstrong i Morón, Judith
  • Lázaro García, Conxi
  • Esteller, Manel
Purpose: autism spectrum disorders are associated with defects in social response and communication that often occur in the context of intellectual disability. Rett syndrome is one example in which epilepsy, motor impairment, and motor disturbance may co-occur. Mutations in histone demethylases are known to occur in several of these syndromes. Herein, we aimed to identify whether mutations in the candidate histone demethylase JMJD1C (jumonji domain containing 1C) are implicated in these disorders. Methods: we performed the mutational and functional analysis of JMJD1C in 215 cases of autism spectrum disorders, intellectual disability, and Rett syndrome without a known genetic defect. Results: we found seven JMJD1C variants that were not present in any control sample (~ 6,000) and caused an amino acid change involving a different functional group. From these, two de novo JMJD1C germline mutations were identified in a case of Rett syndrome and in a patient with intellectual disability. The functional study of the JMJD1C mutant Rett syndrome patient demonstrated that the altered protein had abnormal subcellular localization, diminished activity to demethylate the DNA damage-response protein MDC1, and reduced binding to MECP2. We confirmed that JMJD1C protein is widely expressed in brain regions and that its depletion compromises dendritic activity. Conclusions: our findings indicate that mutations in JMJD1C contribute to the development of Rett syndrome and intellectual disability.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia

  • Ferreira, Humberto J.
  • Heyn, Holger
  • Vizoso, Miguel
  • Moutinho, Cátia
  • Vidal, Enrique
  • Gomez, A
  • Martínez Cardús, Anna
  • Simó-Riudalbas, Laia
  • Moran, Sebastian
  • Jost, E
  • Esteller, Manel
Close to half of de novo acute myeloid leukemia (AML) cases do not exhibit any cytogenetic aberrations. In this regard, distortion of the DNA methylation setting and the presence of mutations in epigenetic modifier genes can also be molecular drivers of the disease. In recent years, somatic missense mutations of the DNA methyltransferase 3A (DNMT3A) have been reported in ~20% of AML patients; however, no obvious critical downstream gene has been identified that could explain the role of DNMT3A in the natural history of AML. Herein, using whole-genome bisulfite sequencing and DNA methylation microarrays, we have identified a key gene undergoing promoter hypomethylation-associated transcriptional reactivation in DNMT3 mutant patients, the leukemogenic HOX cofactor MEIS1. Our results indicate that, in the absence of mixed lineage leukemia fusions, an alternative pathway for engaging an oncogenic MEIS1-dependent transcriptional program can be mediated by DNMT3A mutations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia

  • Anadón, C.
  • van Tetering, G.
  • Ferreira, H. J.
  • Moutinho, Catia|||0000-0003-3885-0847
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Soler, Marta|||0000-0002-6656-957X
  • Heyn, Holger|||0000-0002-3276-1889
  • Moran, S.|||0000-0003-4192-8983
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Setien, F.
  • Vidal, A.
  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Guil, Sonia|||0000-0002-2257-3331
  • Esteller, M.|||0000-0003-4490-6093
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

  • Janin, Maxime|||0000-0003-1013-4128
  • Ortiz-Barahona, V.
  • de Moura, M. C.
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Soler, Marta|||0000-0002-6656-957X
  • Nachmani, D.
  • Pelletier, Joffrey|||0000-0001-9174-044X
  • Schumann, U.
  • Calleja-Cervantes, María Eréndira|||0000-0003-0688-0793
  • Moran, S.|||0000-0003-4192-8983
  • Guil, Sonia|||0000-0002-2257-3331
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Piñeyro, David|||0000-0001-5633-3339
  • Perez-Salvia, Montserrat
  • Rosselló-Tortella, M.
  • Piqué, Laia
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Vidal, August|||0000-0001-5727-2099
  • Martínez-Iniesta, M.
  • Martín-Tejera, J. F.
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Arias, Alexandra
  • Cuartas, Isabel
  • Aransay, Ana M.|||0000-0002-8271-612X
  • La Madrid, A. M.
  • Carcaboso, Angel M.|||0000-0002-8485-426X
  • Santa-Maria, V.
  • Mora, J.
  • Fernández, Agustín F.|||0000-0002-3792-4085
  • Fraga, M. F.
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Graus Ribas, Francesc|||0000-0002-8924-8322
  • Vidal, Noemí|||0000-0002-2852-6667
  • Martinez, Fina|||0000-0002-0940-1025
  • Tortosa, Avelina|||0000-0002-9080-2976
  • Carrato, Cristina|||0000-0002-1953-8287
  • Balañá, Carmen|||0000-0003-0771-0390
  • Boudreau, M. W.
  • Hergenrother, P. J.
  • Kötter, P.
  • Entian, K. D.
  • Hench, Jürgen
  • Frank, Stephan|||0000-0001-6165-0187
  • Mansouri, S.
  • Zadeh, G.
  • Dans, P. D.
  • Orozco López, Modesto|||0000-0002-8608-3278
  • Thomas, Gareth J.
  • Blanco, Sandra
  • Seoane Suárez, Joan|||0000-0002-6541-5974
  • Preiss, T.
  • Pandolfi, P. P.
  • Esteller, M.|||0000-0003-4490-6093
Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dynamic epigenetic age mosaicism in the human atherosclerotic artery

  • Zaina, Silvio|||0000-0001-6589-076X
  • Esteller, M|||0000-0003-4490-6093
  • Gonçalves, Isabel|||0000-0002-2935-0181
  • Lund, Gertrud|||0000-0003-3556-8520
Accelerated epigenetic ageing, a promising marker of disease risk, has been detected in peripheral blood cells of atherosclerotic patients, but evidence in the vascular wall is lacking. Understanding the trends of epigenetic ageing in the atheroma may provide insights into mechanisms of atherogenesis or identify targets for molecular therapy. We surveyed DNA methylation age in two human artery samples: a set of donor-matched, paired atherosclerotic and healthy aortic portions, and a set of carotid artery atheromas. The well-characterized pan-tissue Horvath epigenetic clock was used, together with the Weidner whole-blood-specific clock as validation. For the first time, we document dynamic DNA methylation age mosaicism of the vascular wall that is atherosclerosis-related, switches from acceleration to deceleration with chronological ageing, and is consistent in human aorta and carotid atheroma. At CpG level, the Horvath epigenetic clock showed modest differential methylation between atherosclerotic and healthy aortic portions, weak association with atheroma histological grade and no clear evidence for participation in atherosclerosis-related cellular pathways. Our data suggest caution when assigning a unidirectional DNA methylation age change to the atherosclerotic arterial wall. Also, the results support previous conclusions that epigenetic ageing reflects non-disease-specific cellular alterations.